References
- Akkiraju, H., & Nohe, A. (2015). Role of chondrocytes in cartilage formation, progression of osteoarthritis and cartilage regeneration. Journal of Developmental Biology, 3(4), 177–192. https://doi.org/https://doi.org/10.3390/jdb3040177
- Baragi, V. M., Becher, G., Bendele, A. M., Biesinger, R., Bluhm, H., Boer, J., Deng, H., Dodd, R., Essers, M., Feuerstein, T., Gallagher, B. M., Gege, C., Hochgürtel, M., Hofmann, M., Jaworski, A., Jin, L., Kiely, A., Korniski, B., Kroth, H., … Xia, B. (2009). A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis and Rheumatism, 60(7), 2008–2018. https://doi.org/https://doi.org/10.1002/art.24629
- Bijlsma, J. W., Berenbaum, F., & Lafeber, F. P. (2011). Osteoarthritis: An update with relevance for clinical practice. The Lancet, 377(9783), 2115–2126. https://doi.org/https://doi.org/10.1016/S0140-6736(11)60243-2
- Borkakoti, N., Winkler, F. K., Williams, D. H., D'Arcy, A., Broadhurst, M. J., Brown, P. A., Johnson, W. H., & Murray, E. J. (1994). Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nature Structural Biology, 1(2), 106–110. https://doi.org/https://doi.org/10.1038/nsb0294-106
- Brandt, K. D., Dieppe, P., & Radin, E. L. (2008). Etiopathogenesis of osteoarthritis. Rheumatic Diseases Clinics of North America, 34(3), 531–559. https://doi.org/https://doi.org/10.1016/j.rdc.2008.05.011
- Caron, J. P., Fernandes, J. C., Martel‐Pelletier, J., Tardif, G., Mineau, F., Geng, C., & Pelletier, J. P. (1996). Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 39(9), 1535–1544. https://doi.org/https://doi.org/10.1002/art.1780390914
- Case, D. A., Darden, T. A., Cheatham, T. E., Simmerling, C. L., Wang, J., Duke, R. E., … Merz, K. M. (2012). AMBER 12 University of California. San Francisco.
- Chan, C. M., Macdonald, C. D., Litherland, G. J., Wilkinson, D. J., Skelton, A., Europe-Finner, G. N., & Rowan, A. D. (2017). Cytokine-induced MMP13 expression in human chondrocytes is dependent on activating transcription factor 3 (ATF3) regulation. The Journal of Biological Chemistry, 292(5), 1625–1636. https://doi.org/https://doi.org/10.1074/jbc.M116.756601
- Chen, J. M., Nelson, F. C., Levin, J. I., Mobilio, D., Moy, F. J., Nilakantan, R., Zask, A., & Powers, R. (2000). Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. Journal of the American Chemical Society, 122(40), 9648–9654. https://doi.org/https://doi.org/10.1021/ja001547g
- Chowdhury, T. T., Schulz, R. M., Rai, S. S., Thuemmler, C. B., Wuestneck, N., Bader, A., & Homandberg, G. A. (2010). Biomechanical modulation of collagen fragment-induced anabolic and catabolic activities in chondrocyte/agarose constructs. Arthritis Research & Therapy, 12(3), 1–15. https://doi.org/https://doi.org/10.1186/ar3009
- Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., Yoshizaki, K., Nishimoto, N., Kishimoto, T., & Panayi, G. S. (2002). Therapeutic benefit of blocking interleukin-6 activity with an anti–interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis & Rheumatism, 46(12), 3143–3150. https://doi.org/https://doi.org/10.1002/art.10623
- Clark, I. M., & Parker, A. E. (2003). Metalloproteinases: Their role in arthritis and potential as therapeutic targets. Expert Opinion on Therapeutic Targets, 7(1), 19–34. https://doi.org/https://doi.org/10.1517/14728222.7.1.19
- Edwards, R. L., Luis, P. B., Varuzza, P. V., Joseph, A. I., Presley, S. H., Chaturvedi, R., & Schneider, C. (2017). The anti-inflammatory activity of curcumin is mediated by its oxidative metabolites. The Journal of Biological Chemistry, 292(52), 21243–21252. https://doi.org/https://doi.org/10.1074/jbc.RA117.000123
- Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. https://doi.org/https://doi.org/10.1021/jm0306430
- Golub, L. M., McNamara, T. F., Ryan, M. E., Kohut, B., Blieden, T., Payonk, G., Sipos, T., & Baron, H. J. (2001). Adjunctive treatment with subantimicrobial doses of doxycycline: Effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. Journal of Clinical Periodontology, 28(2), 146–156. https://doi.org/https://doi.org/10.1034/j.1600-051x.2001.028002146.x
- Goulart, M., Partar, D., Cunha, L., & Zung, S. (2019). AB0792 cucumin in osteoarthritis treatment: The present state of evidence. Annals of the Rheumatic Diseases, 78(Suppl 2), 1867–1867. https://doi.org/https://doi.org/10.1136/annrheumdis-2019-eular.5744.
- Hattori, N., Mochizuki, S., Kishi, K., Nakajima, T., Takaishi, H., D'Armiento, J., & Okada, Y. (2009). MMP-13 plays a role in keratinocyte migration, angiogenesis, and contraction in mouse skin wound healing. The American Journal of Pathology, 175(2), 533–546. https://doi.org/https://doi.org/10.2353/ajpath.2009.081080
- Hsieh, C. Y. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research, 21(2895), e2900.
- Johnson, A. R., Pavlovsky, A. G., Ortwine, D. F., Prior, F., Man, C.-F., Bornemeier, D. A., Banotai, C. A., Mueller, W. T., McConnell, P., Yan, C., Baragi, V., Lesch, C., Roark, W. H., Wilson, M., Datta, K., Guzman, R., Han, H.-K., & Dyer, R. D. (2007). Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. The Journal of Biological Chemistry, 282(38), 27781–27791. https://doi.org/https://doi.org/10.1074/jbc.M703286200
- Li, H., Wang, D., Yuan, Y., & Min, J. (2017). New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis. Arthritis Research & Therapy, 19(1), 248. https://doi.org/https://doi.org/10.1186/s13075-017-1454-2
- Li, K., Tay, F. R., & Yiu, C. K. Y. (2020). The past, present and future perspectives of matrix metalloproteinase inhibitors. Pharmacology & Therapeutics, 207, 107465. https://doi.org/https://doi.org/10.1016/j.pharmthera.2019.107465
- Little, C. B., Barai, A., Burkhardt, D., Smith, S. M., Fosang, A. J., Werb, Z., Shah, M., & Thompson, E. W. (2009). Matrix metalloproteinase 13–deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis & Rheumatism, 60(12), 3723–3733. https://doi.org/https://doi.org/10.1002/art.25002
- Malemud, C. J. (2019). Inhibition of MMPs and ADAM/ADAMTS. Biochemical Pharmacology, 165, 33–40. https://doi.org/https://doi.org/10.1016/j.bcp.2019.02.033
- Pochetti, G., Montanari, R., Gege, C., Chevrier, C., Taveras, A. G., & Mazza, F. (2009). Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8). Journal of Medicinal Chemistry, 52(4), 1040–1049. https://doi.org/https://doi.org/10.1021/jm801166j
- Preshaw, P. M., Hefti, A. F., Novak, M. J., Michalowicz, B. S., Pihlstrom, B. L., Schoor, R., Trummel, C. L., Dean, J., Dyke, T. E. V., Walker, C. B., & Bradshaw, M. H. (2004). Subantimicrobial dose doxycycline enhances the efficacy of scaling and root planing in chronic periodontitis: A multicenter trial. Journal of Periodontology, 75(8), 1068–1076. https://doi.org/https://doi.org/10.1902/jop.2004.75.8.1068
- Renkiewicz, R., Qiu, L., Lesch, C., Sun, X., Devalaraja, R., Cody, T., Kaldjian, E., Welgus, H., & Baragi, V. (2003). Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis and Rheumatism, 48(6), 1742–1749. https://doi.org/https://doi.org/10.1002/art.11030
- Rose, B. J., & Kooyman, D. L. (2016). A tale of two joints: The role of matrix metalloproteases in cartilage biology. Disease Markers, 2016, 4895050. https://doi.org/https://doi.org/10.1155/2016/4895050
- Sabatini, M., Lesur, C., Thomas, M., Chomel, A., Anract, P., de Nanteuil, G., & Pastoureau, P. (2005). Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. Arthritis & Rheumatism, 52(1), 171–180. https://doi.org/https://doi.org/10.1002/art.20900
- Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-aided Molecular Design, 27(3), 221–234. https://doi.org/https://doi.org/10.1007/s10822-013-9644-8
- Schneider, C., Gordon, O. N., Edwards, R. L., & Luis, P. B. (2015). Degradation of curcumin: From mechanism to biological implications. Journal of Agricultural and Food Chemistry, 63(35), 7606–7614. https://doi.org/https://doi.org/10.1021/acs.jafc.5b00244
- Sharma, L. (2016). Osteoarthritis year in review 2015: Clinical. Osteoarthritis and Cartilage, 24(1), 36–48. https://doi.org/https://doi.org/10.1016/j.joca.2015.07.026
- Shen, L., Liu, C. C., An, C. Y., & Ji, H. F. (2016). How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies. Scientific Reports, 6(1), 20872–20810. https://doi.org/https://doi.org/10.1038/srep20872
- Shep, D., Khanwelkar, C., Gade, P., & Karad, S. (2019). Safety and efficacy of curcumin versus diclofenac in knee osteoarthritis: A randomized open-label parallel-arm study. Trials, 20(1), 214. https://doi.org/https://doi.org/10.1186/s13063-019-3327-2
- Shi, J., Son, M.-Y., Yamada, S., Szabova, L., Kahan, S., Chrysovergis, K., Wolf, L., Surmak, A., & Holmbeck, K. (2008). Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Developmental Biology, 313(1), 196–209. https://doi.org/https://doi.org/10.1016/j.ydbio.2007.10.017
- Shiomi, T., Lemaître, V., D'Armiento, J., & Okada, Y. (2010). Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathology International, 60(7), 477–496. https://doi.org/https://doi.org/10.1111/j.1440-1827.2010.02547.x
- Taylor, S. J., Abeywardane, A., Liang, S., Muegge, I., Padyana, A. K., Xiong, Z., Hill-Drzewi, M., Farmer, B., Li, X., Collins, B., Li, J. X., Heim-Riether, A., Proudfoot, J., Zhang, Q., Goldberg, D., Zuvela-Jelaska, L., Zaher, H., Li, J., & Farrow, N. A. (2011). Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. Journal of Medicinal Chemistry, 54(23), 8174–8187. https://doi.org/https://doi.org/10.1021/jm201129m
- Wang, M., Sampson, E. R., Jin, H., Li, J., Ke, Q. H., Im, H. J., & Chen, D. (2013). MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Research & Therapy, 15(1), R5–11. https://doi.org/https://doi.org/10.1186/ar4133
- Yang, C. C., Lin, C. Y., Wang, H. S., & Lyu, S. R. (2013). Matrix metalloproteases and tissue inhibitors of metalloproteinases in medial plica and pannus-like tissue contribute to knee osteoarthritis progression. PLoS One, 8(11), e79662 https://doi.org/https://doi.org/10.1371/journal.pone.0079662